Aprea Therapeutics (APRE) Return on Capital Employed (2023 - 2026)
Aprea Therapeutics (APRE) posted quarterly Return on Capital Employed of 47.51% for Q1 2026, up 3390.0% year-over-year from 1.36% in Q1 2025, and up 55.62% quarter-over-quarter from 107.04% in Q4 2025.
Aprea Therapeutics (APRE) Return on Capital Employed (2023 - 2026) Analysis & Trends
Aprea Therapeutics (APRE) has reported Return on Capital Employed for 4 consecutive years, with 47.51% the latest figure, recorded in Q1 2026.
- In Q1 2026, Return on Capital Employed rose 3390.0% year-over-year to 47.51%; the TTM figure through Mar 2026 stood at 47.51% (up 3390.0% YoY), while the FY2025 annual figure was 76.98%, down 521.0% from the prior year.
- Return on Capital Employed rose to 47.51% in Q1 2026 per APRE's latest filing, from 107.04% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 47.51% in Q1 2026 and bottomed at 409.3% in Q1 2023.
- Historically, Return on Capital Employed has averaged 97.97% across 4 years, with a median of 64.87% in 2024.
- Annual changes were most pronounced in 2024 — Return on Capital Employed jumped 35321 bps — and 2025, when it plunged 4563 bps.
- Aprea Therapeutics' Return on Capital Employed stood at 78.05% in 2023, then rose by 17 bps to 64.87% in 2024, then slumped by 65 bps to 107.04% in 2025, then surged by 56 bps to 47.51% in 2026.
- Business Quant data shows APRE's Return on Capital Employed at 47.51% in Q1 2026, 107.04% in Q4 2025, and 105.2% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | Aprea Therapeutics | 34.25 Mn | 34.25 Mn | - | -31.59% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -31.59% |
| Mar 31, 2026 | -47.51% |
| Dec 31, 2025 | -107.04% |
| Sep 30, 2025 | -105.20% |
| Jun 30, 2025 | -94.86% |
| Mar 31, 2025 | -81.41% |
| Dec 31, 2024 | -64.87% |
| Sep 30, 2024 | -59.57% |
| Jun 30, 2024 | -49.83% |
| Mar 31, 2024 | -56.09% |
| Dec 31, 2023 | -78.05% |
| Sep 30, 2023 | -62.66% |
| Jun 30, 2023 | -57.30% |
| Mar 31, 2023 | -409.30% |